The extensive pretrial proceedings mean the first Ozempic bellwether trials are unlikely to begin until at least 2026 or 2027.
Lawsuit claims Novo Nordisk's failures to warn about the risk of gastroparesis and Ileus from Ozempic were "wanton, willful, fraudulent, reckless acts."
Findings come amid continuing concerns drug maker failed to inform clinical trial subjects that their genetics could increase the risk of brain swelling from Kisunla.
Researchers have found that users of Ozempic, Mounjaro and similar drugs are less likely to experience opioid overdoses or alcoholism.
Inadequate bowel prep due to side effects of Ozempic and Mounjaro carries significant risk of missed lesions, canceled procedures and other complications.
Novo Nordisk allegedly knew for years about the risk that Ozempic and Rybelsus may cause ileus and other severe gastrointestinal side effects, but failed to warn doctors or patients.
Side effects of Mounjaro caused cyclical vomiting that required emergency medical treatment, lawsuit claims.
Kentucky woman claims Ozempic caused stomach paralysis, which resulted in the need for emergency medical treatment and left her with permanent injuries.
Side effects of Ozempic and similar GLP-1 drugs approved for treatment of diabetes and weight loss can delay gastric emptying and increase the risk of aspiration during upper GI endoscopic procedures.
Warning labels provided for users of the GLP-1 diabetes drug downplayed the risk of gastrointestinal side effects from Trulicity, lawsuit states.
